Key Highlights

  • Net loss was USD 3.2 million, or USD 0.07 per share, in the third quarter against USD 5.3 million, or USD 0.15, a year earlier; the nine-month net loss was USD 13.4 million versus USD 15.6 million.
  • Research and development spending fell to USD 1.42 million from USD 2.85 million, about 50% lower by calculation, while general and administrative expense eased to USD 1.78 million from USD 1.94 million.
  • Cash and cash equivalents were USD 11.7 million at September 30, 2026, after USD 12.5 million of operating cash outflow over nine months, and the company said it needs more Capital beyond the second quarter of 2027.
  • In the quarter the company sold 978,260 shares through its at-the-market program at an average USD 1.88 for gross proceeds of USD 1.8 million, taking program sales to 10,389,769 shares and USD 25.7 million.

Lower Rexaceract Spending Shrinks the Quarterly Loss

Gain Therapeutics (NASDAQ:GANX) filed its Quarterly Report on November 10, 2026, for the three months ended September 30, 2026. The biotechnology company uses a computational platform called Magellan to find new binding sites on proteins and develop small molecule drugs, with lead candidate rexaceract aimed at Parkinson's disease. It has no approved product and no product revenue. The loss from operations was USD 3.20 million against USD 4.79 million, and the net loss was USD 3.16 million against USD 5.28 million. For nine months, Research and Development fell to USD 6.32 million from USD 7.87 million.

Phase 2 Plans and Phase 1b Stabilization Data

The FDA authorized the Investigational New Drug application for a Phase 2 study of rexaceract in June 2026. The company plans to start the study in the first quarter of 2027 at sites in the United States, Australia and Europe, and expects to submit an amended protocol in the fourth quarter of 2026. Part 2 of the Phase 1b study is due to finish in the fourth quarter of 2026. In October 2026, it presented open-label extension data for 13 evaluable patients showing stable Parkinson's motor scores over 360 days of dosing, and a link between changes in a cerebrospinal fluid marker and those scores. The company says this supports a disease-modifying hypothesis, which only later controlled trials can test.

Going Concern Doubt and At-the-Market Dilution

Management said projected cash outflows raise substantial doubt about continuing as a Going Concern for 12 months from issuance, and that more capital is needed to fund operations beyond the second quarter of 2027. The accumulated Deficit was USD 114.8 million, and the company has raised USD 123 million of gross Equity proceeds since inception. Selling shares through an at-the-market program adds shares, which dilutes existing holders, and warrants cover another 5.3 million shares at a weighted-average USD 2.37. The company is also evaluating licensing and Partnership Options for rexaceract but said there is no assurance any deal will result. For a small company that depends on equity sales, small trades can move the quoted price.

Where Things Stand

Because lower spending narrowed the loss without adding Revenue or runway. Gain Therapeutics (NASDAQ:GANX) cut research spending by about half and trimmed the net loss to USD 3.2 million, yet cash of USD 11.7 million and USD 12.5 million of nine-month operating outflow led management to flag going concern doubt. Financing is likely to come from equity sales, partnerships or other sources, none of which is assured. Next markers are the fourth-quarter amended Phase 2 protocol, completion of Phase 1b Part 2, the planned first-quarter 2027 Phase 2 start and any funding or licensing announcement before mid-2027.